• Home
  • P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.

P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.

Author List
J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely
Publication
Journal of Thoracic Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/79291379
Publication Year
2019
Publication Title
J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2019 Oct 1; 14(10):s578.